

Cambridge Pharmaceuticals Limited

REPORT AND FINANCIAL STATEMENTS

for the year ended
31 March 2015



Cambridge Pharmaceuticals Limited

DIRECTORS AND OFFICERS

DIRECTORS

BL Eghiayan

SECRETARY

BL Eghiayan

REGISTERED OFFICE

23 Wigmore Street
London W1U 1PL

Cambridge Pharmaceuticals Limited

DIRECTORS' REPORT

The directors submit their report and the financial statements of Cambridge Pharmaceuticals Limited for the year ended 31 March 2014.

PRINCIPAL ACTIVITIES

The company was dormant throughout the period.

REVIEW OF THE BUSINESS

The company remained dormant throughout the period.

DIRECTORS

The following directors have held office since 1 April 2014:

M Avedissian (Resigned 5th February 2015)
BL Eghiayan

This report has been prepared in accordance with the special provisions of the Companies Act 2006 relating to small companies.

On behalf of the board



B L Eghiayan
Director

Cambridge Pharmaceuticals Limited

DIRECTORS' RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors are required to:

- a. select suitable accounting policies and then apply them consistently;
- b. make judgements and estimates that are reasonable and prudent;
- c. prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the requirements of the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Cambridge Pharmaceuticals Limited

BALANCE SHEET

31 March 2015

	<i>Notes</i>	2015 £	2014 £
CURRENT ASSETS			
Debtors	3	102	102
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>102</u>	<u>102</u>
CAPITAL AND RESERVES			
Called up share capital	4	102	102
SHAREHOLDERS' FUNDS		<u>102</u>	<u>102</u>


For the period ended 31 March 2015 the company was entitled to exemption from audit under section 480 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibility for:

- a. Complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

Approved by the board and authorised for issue on



B L Eghian
Director

Cambridge Pharmaceuticals Limited

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 March 2015

1 BASIS OF ACCOUNTING

The accounts have been prepared under the historical cost convention.

2 DEBTORS

	2015 £	2014 £
--	-----------	-----------

Due within one year:

Other debtors

102

102

3 SHARE CAPITAL

	2015 £	2014 £
--	-----------	-----------

Authorised:

102 ordinary shares of £1 each

102

102

Allotted, issued and fully paid:

102 ordinary shares of £1 each

102

102

During the year, the shares owned by Dilazar Limited and AMA Group International Limited were transferred to B Eghiayan at par.

4 RECONCILIATION OF MOVEMENT IN SHAREHOLDERS' FUNDS

	2015 £	2014 £
--	-----------	-----------

Result for the financial period

Share Capital issued

-

-

-

2

Net addition to shareholders' funds

-

2

Opening shareholders' funds

102

100

Closing shareholders' funds

102

102